FDA to expedite review of Teva drug for movement disorder

"There remains a significant unmet medical need in tardive dyskinesia," said Michael Hayden, chief scientific officer at Teva.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news